Navigation Links
Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
Date:10/11/2007

ANN ARBOR, Mich., Oct. 11 /PRNewswire/ -- Compendia Bioscience, Inc. today announced the receipt of a $2.4 million SBIR Fast Track Award from the National Cancer Institute to support the project entitled "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development".

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

Compendia co-founder Dan Rhodes Ph.D., who will serve as the principal investigator for this project, will assume a full time position at Compendia Bioscience as Chief Executive Officer. Current CEO John Freshley will remain with the company as Chief Business Officer overseeing sales, marketing and corporate development.

"We are thrilled with this award from the NCI and are looking forward to executing the project, which we expect will lead to increased applicability of Oncomine Professional to drug discovery and development," said Dr. Rhodes. "And on a personal level, I am excited to have the opportunity to increase my level of commitment to Compendia."

"Compendia was founded in 2006 to extend Oncomine the commercial sector. Over the past year we have seen ever increasing acceptance of Oncomine in the biopharmaceutical arena, and with that growing sales, marketing, and business development demands," commented John Freshley. "I am looking forward to concentrating on the continued commercial adaptation of this important product."

Oncomine, a dynamic system that combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization, facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.

The NIH Fast-Track application process expedites award decisions and funding of SBIR Phase II applications for scientifically meritorious projects that have a high potential for commercialization. The Fast-Track process allows Phase I and II grant applications to be submitted and reviewed together.

About Compendia Bioscience, Inc. Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes."


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... to announce that Biohaven has issued today the following ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical ... that the U.S. Food and Drug Administration ("FDA") has ... drug candidate BHV-0223, an orally dissolving tablet being developed ...
(Date:12/8/2016)... 8, 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... intratumoral cancer immunotherapies, today announced financial results for ... "We are delivering on our commitment to address ... IL-12. We are pleased with the early clinical ... and we are focused on advancing our lead ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment ... and President of Eurofins Scientific Inc. (ESI). Mr. ... his proven professional and entrepreneurial experience in leading international business teams. ... US food testing market to uphold Eurofins, status as the global ... ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
Breaking Biology News(10 mins):